ETHZilla 

$0.43
110
-$0.03-6.52% Friday 19:59

Statistics

Day High
0.44
Day Low
0.36
52W High
0.44
52W Low
0.36
Volume
463,997
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

25FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-0.85
-0.52
-0.18
0.15
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATNFW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with 180 Life Sciences' novel therapeutic approaches.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing space, directly competing with 180 Life Sciences in developing treatments for diseases with unmet medical needs.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology sector, potentially competing with 180 Life Sciences in the field of genetic and autoimmune diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on creating transformative medicines for people with serious diseases, which aligns with 180 Life Sciences' mission, making them competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with 180 Life Sciences in developing novel therapeutics for various diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with 180 Life Sciences in the development of novel treatments for genetic and other diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with 180 Life Sciences in the rare disease space.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics, competing with 180 Life Sciences in the development of innovative treatments for diseases.

About

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Show more...
CEO
Mr. Lloyd Blair Jordan L.L.B., M.B.A.
Employees
4
Country
US
ISIN
US68236V1127

Listings

0 Comments

Share your thoughts

FAQ

What is ETHZilla stock price today?
The current price of ATNFW is $0.43 USD — it has decreased by -6.52% in the past 24 hours. Watch ETHZilla stock price performance more closely on the chart.
What is ETHZilla stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange ETHZilla stocks are traded under the ticker ATNFW.
Is ETHZilla stock price growing?
ATNFW stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year ETHZilla has showed a +6,042.86% increase.
What is ETHZilla revenue for the last year?
ETHZilla revenue for the last year amounts to 0 USD.
What is ETHZilla net income for the last year?
ATNFW net income for the last year is -14.18M USD.
How many employees does ETHZilla have?
As of April 02, 2026, the company has 4 employees.
In which sector is ETHZilla located?
ETHZilla operates in the Health Care sector.
When did ETHZilla complete a stock split?
The last stock split for ETHZilla was on December 19, 2022 with a ratio of 1:20.
Where is ETHZilla headquartered?
ETHZilla is headquartered in Palo Alto, US.